Sökning: WFRF:(Ferrante Marc)
> (2019) >
Vedolizumab in Refr...
Vedolizumab in Refractory Microscopic Colitis : An International Case Series
-
- Riviere, Pauline (författare)
- Katholieke Univ Leuven, Belgium
-
- Münch, Andreas, 1970- (författare)
- Linköpings universitet,Avdelningen för neuro- och inflammationsvetenskap,Medicinska fakulteten,Region Östergötland, Magtarmmedicinska kliniken
-
- Michetti, Pierre (författare)
- Gastroenterol La Source Beaulieu, Switzerland
-
visa fler...
-
- Chande, Nilesh (författare)
- Western Univ, Canada
-
- de Hertogh, Gert (författare)
- Katholieke Univ Leuven, Belgium
-
- Schoeters, Patrick (författare)
- AZA Herentals, Belgium
-
- Ferrante, Marc (författare)
- Katholieke Univ Leuven, Belgium
-
- Vermeire, Severine (författare)
- Katholieke Univ Leuven, Belgium
-
- Van Assche, Gert (författare)
- Katholieke Univ Leuven, Belgium
-
visa färre...
-
(creator_code:org_t)
- 2018-10-17
- 2019
- Engelska.
-
Ingår i: Journal of Crohn's & Colitis. - : Oxford University Press. - 1873-9946 .- 1876-4479. ; 13:3, s. 337-340
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background Evidence for second-line therapy in patients with microscopic colitis [MC] failing budesonide is scarce, although anti-tumour necrosis factors [anti-TNFs], methotrexate and azathioprine have been reported to be effective in small cohort studies. Vedolizumab, a monoclonal antibody targeting 47-integrin, prevents homing of T-cells to the gut. We evaluated clinical remission with vedolizumab in budesonide-refractory MC patients. Methods We solicited gastroenterologists in Europe and Canada for cases of MC treated with vedolizumab. Vedolizumab 300 mg IV was administered at weeks 0, 2 and 6, and then every 8 weeks. Clinical remission and histological remission were defined as less than three stools per day and normalization of histology, respectively, after induction treatment. Results Eleven cases were retrieved (nine females, lymphocytic colitis [LC] n = 5, collagenous colitis [CC] n = 6). Median [interquartile range] disease duration at vedolizumab initiation was 51 [29-70] months. Nine of 11 patients had failed one immunosuppressant and ten of 11 at least one anti-TNF agent. After three infusions of vedolizumab, clinical remission was observed in 5/11 patients [two LC and three CC] of whom three remained well with maintenance therapy [median duration of 13 months]. Biopsies were obtained from 9/11 patients. Histological remission was observed in 3/4 patients with clinical remission [2/3 CC, 1/1 LC] and 0/5 patients without clinical improvement. Conclusion In a series of highly refractory MC patients, vedolizumab induced clinical remission in 5/11 subjects, of whom 75% showed normalized histology. Larger randomized trials are needed to assess the efficacy of vedolizumab in patients with MC.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Gastroenterologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)
Nyckelord
- microscopic colitis; refractory; vedolizumab; treatment outcome
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Riviere, Pauline
-
Münch, Andreas, ...
-
Michetti, Pierre
-
Chande, Nilesh
-
de Hertogh, Gert
-
Schoeters, Patri ...
-
visa fler...
-
Ferrante, Marc
-
Vermeire, Severi ...
-
Van Assche, Gert
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Gastroenterologi
- Artiklar i publikationen
-
Journal of Crohn ...
- Av lärosätet
-
Linköpings universitet